Niraparib Tosylate: A Comprehensive Guide for API Importers, Manufacturers, and Compounding Pharmacies
In the rapidly evolving landscape of oncology therapeutics, Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a cornerstone of targeted cancer treatment.
Among them, Niraparib has distinguished itself through its unique pharmacological profile and broad applicability.
For Niraparib API importers, medicine manufacturers, and compounding pharmacies, understanding the intricacies of Niraparib is not just about adding a product to a portfolio—it’s about engaging with a high-value, high-growth market that demands expertise and precision.
This comprehensive guide explores every aspect of Niraparib, from its scientific foundations to its global market dynamics, providing the insights necessary to make informed decisions and capitalize on emerging opportunities.
What is Niraparib?
Niraparib, often sold as Niraparib Tosyate Salt, appears as a white to off-white powder with excellent solubility, particularly in DMSO, facilitating easier formulation for pharmaceutical manufacturers.
It is an orally administered, potent, and highly selective inhibitor of two enzymes: PARP-1 and PARP-2.
It belongs to the revolutionary class of anti-cancer drugs known as PARP inhibitors. Its primary role is in the maintenance treatment of specific types of gynecological cancers, where it has demonstrated a significant ability to delay cancer progression and improve patient outcomes.
It was initially developed by Tesaro (now part of GSK) and has since become a critical asset in oncologists’ arsenals.
Its development marked a significant advancement in the concept of synthetic lethality, offering a targeted approach to killing cancer cells with specific genetic vulnerabilities while sparing healthy ones.
What are the brand names of Niraparib?
The most widely recognized brand name for Niraparib is Zejula (marketed globally by GSK).
In China, it is also known by the trade name 则乐 (Zé Lè).
API and generic manufacturers must note that the drug is also available under various generic names and brands from different manufacturers in specific markets.
For instance, several bioequivalent generic versions are available from manufacturers in Bangladesh, India, and Laos (e.g., Beacon Pharmaceuticals and Everest Pharmaceuticals), often under names that list “Niraparib” alongside the manufacturer’s branding.
What is Niraparib used for?
Niraparib is approved for the maintenance treatment of specific epithelial ovarian, fallopian tube, and primary peritoneal cancers.
Maintenance therapy is designed to “maintain” the response achieved from initial chemotherapy and prevent or delay the cancer’s return.
Its approved indications, as per the Chinese Health Insurance guidelines (a key market), are :
First-line maintenance treatment: For adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to first-line platinum-based chemotherapy.
Platinum-sensitive recurrent maintenance treatment: For adult patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to platinum-based chemotherapy.
A key differentiator for Niraparib is that it is the first PARP inhibitor approved for use regardless of BRCA mutation or biomarker status, significantly widening its potential patient population.
How Niraparib works? (mechanism of action)
Niraparib’s mechanism of action is a brilliant application of the principle of synthetic lethality.
PARP’s Normal Role: In healthy cells, the PARP enzyme family (particularly PARP-1 and PARP-2) plays a crucial role in detecting and repairing single-strand breaks (SSBs) in DNA.
PARP Inhibition: Niraparib binds to and inhibits PARP-1 and PARP-2 with high affinity (IC50 values of 3.8 nM and 2.1 nM, respectively). This inhibition traps the PARP enzyme on DNA, preventing the repair of routine SSBs.
Conversion to Lethal DSBs: Unrepaired SSBs eventually lead to double-strand breaks (DSBs) during DNA replication.
Synthetic Lethality in Deficient Cells: Normally, cells repair DSBs using the homologous recombination repair (HRR) pathway. BRCA1 and BRCA2 are critical proteins in this pathway. Cancer cells with BRCA mutations (or other HRR deficiencies) have a dysfunctional HRR pathway. They must rely on backup repair mechanisms, which are prone to errors.
When these BRCA-deficient cancer cells are treated with a PARP inhibitor, they encounter a catastrophic problem: they are unable to repair either SSBs (due to PARP inhibition) or the resulting DSBs (due to defective homologous recombination, or HRR). This dual failure leads to an accumulation of irreversible DNA damage and cell death.Activity in HRR-Proficient Cells: Notably, Niraparib has also shown efficacy in tumors without BRCA mutations, suggesting additional mechanisms of action, such as PARP trapping, may contribute to its anti-tumor effects
Niraparib Dosage and Administration
Standard Dosage: The recommended starting dose is 300 mg (three 100 mg capsules) taken orally once daily, with or without food.
Individualized Dosing: A pivotal strategy with Niraparib is the use of an individualized starting dose based on baseline patient characteristics. Clinical data showed that patients with a baseline body weight <77 kg or a platelet count <150,000/µL had a higher incidence of hematologic toxicities. For these patients, a starting dose of 200 mg (two 100 mg capsules) is recommended once daily to improve tolerability while maintaining efficacy.
Timing: Treatment should be initiated within 8 weeks of completing the last dose of platinum-based chemotherapy. Patients are advised to take the capsules at approximately the same time each day. Taking it at bedtime can help mitigate the common side effect of nausea.
Dose Modifications: The management of adverse reactions often requires dose interruptions and/or reductions. The dose can be reduced first to 200 mg daily, then to 100 mg daily if necessary.
Niraparib Precautions and Drug Interactions
Precautions:
Hematologic Toxicity: Can cause life-threatening myelosuppression, including thrombocytopenia, anemia, and neutropenia. Weekly blood counts are required for the first month, then monthly for the next 11 months, and periodically thereafter.
Hypertension and Hypertensive Crisis: Hypertension is a known side effect. Blood pressure should be monitored monthly for the first year and regularly thereafter. It should be well-controlled both before and during treatment.
Embryo-Fetal Toxicity: Can cause fetal harm. Patients must use effective contraception during treatment and for at least 6 months after the last dose.
Drug Interactions:
Strong CYP3A Inducers: Concomitant use with drugs such as rifampin, carbamazepine, or St. John’s Wort should be avoided, as they can decrease the plasma concentration of niraparib, thereby reducing its efficacy.
UGT1A1 Inhibitors: Drugs that inhibit UGT1A1 may increase the concentration of Niraparib’s major metabolite.
Antacids and PPIs: A critical note for formulators and pharmacists: Proton Pump Inhibitors (PPIs), such as omeprazole, can significantly reduce the bioavailability of Niraparib, decreasing its Cmax and AUC by up to 50%. It necessitates careful timing of administration or a reconsideration of concomitant medication.
What are the side effects of Niraparib?
Understanding the side effect profile is crucial for managing patient care and developing supportive care products.
Very Common ( >20% incidence):
Hematologic: Thrombocytopenia (61%), Anemia (50%), Neutropenia (30%). These are the most prominent and require vigilant monitoring.
Gastrointestinal: Nausea (74%), Vomiting (42%), Constipation (40%), Abdominal pain, Diarrhea
General: Fatigue (60-80%), Headache (26%), Insomnia (23%), Palpitations, Decreased appetite.
Common (10-20% incidence):
Hypertension (20%), Rash, Dizziness, Back pain, Cough, Dyspnea.
Management: Most side effects are manageable through dose interruptions, reductions, and supportive care (e.g., antiemetics for nausea, antihypertensives for blood pressure control, transfusions for severe anemia).
Can Niraparib cause pain in scar tissue?
It is a less commonly reported side effect.
While the primary side effects are well-documented hematologic and GI toxicities, musculoskeletal pain is a known adverse reaction.
Some patients report generalized musculoskeletal pain, which could theoretically include discomfort in areas of previous surgery or scar tissue.
However, it is neither specifically highlighted nor a common concern in the major clinical trials or prescribing information.
Patients experiencing such pain should be evaluated to rule out other causes.
Do you lose hair with Niraparib?
Alopecia (hair loss) is not a commonly reported or prominent side effect of Niraparib.
Unlike traditional chemotherapy, which frequently causes significant hair loss by targeting all rapidly dividing cells, targeted therapies like PARP inhibitors have a different toxicity profile.
While some patients may experience mild hair thinning or changes in texture, severe, overt hair loss is uncommon.
It is a significant differentiating factor for patient quality of life and is an essential point for pharmacists and clinicians to communicate to patients to manage expectations.
Does Niraparib affect sleeping?
Yes, Niraparib can significantly impact sleep.
Clinical trial data from a pooled safety population of over 1,300 patients reported an insomnia incidence rate of 23%.
The exact mechanism is not fully understood, but it could be related to the drug’s overall impact on the central nervous system or a secondary effect of other symptoms like anxiety, fatigue, or hormonal changes.
Patients are advised to practice good sleep hygiene. In cases of severe insomnia, healthcare providers may consider pharmacological interventions like sedative-hypnotics (e.g., zopiclone, zolpidem).
Niraparib vs. Other Medications (Olaparib, Rucaparib)
| Feature | Niraparib (Zejula) | Olaparib (Lynparza) | Rucaparib (Rubraca) |
|---|---|---|---|
| Dosing | 300 mg QD (Once Daily) | 300 mg BID (Twice Daily) | 600 mg BID (Twice Daily) |
| Biomarker Status | Effective with or without BRCA mutation | Initially approved for BRCA-mutated cancers | Approved for BRCA-mutated cancers |
| Key Differentiator | Individualized starting dose, broadest label | First to market, extensive data | |
| Common AEs | Thrombocytopenia, Hypertension, Insomnia | Anemia, Nausea, Fatigue | AST/ALT increase, Fatigue |
| Pros for Patients | QD dosing improves adherence | Longest real-world experience | |
| Pros for Pharma | Broader target population, simpler dosing regimen |
Niraparib’s once-daily dosing offers a potential advantage in patient adherence compared with BID alternatives such as Olaparib and Rucaparib.
Its efficacy in a broader patient population (BRCA wild-type) also makes it a versatile choice.
How long does Niraparib take to work?
Niraparib begins working at the molecular level immediately after the first dose.
However, the clinical measurable effect—such as preventing cancer progression—is evaluated over months.
The primary evidence of its “work” is the extension of progression-free survival (PFS).
In the pivotal NOVA trial, the median time to progression in the placebo group was 3.9 to 5.5 months.
Niraparib demonstrated a statistically significant extension of this period, with median PFS of 21 months in the gBRCA-mutated cohort and 9.3 months in the non-gBRCA-mutated cohort.
Patients do not typically “feel” it working in the same way they might feel a painkiller working; the absence of disease progression on scans measures its success.
How long does Niraparib stay in your system?
The elimination half-life of Niraparib is approximately 36 hours (range 30-40 hours) after multiple doses.
Pharmacokinetically, it takes about 5 to 6 half-lives for a drug to be almost eliminated from the body.
Therefore, it would take roughly 7.5 to 9 days for Niraparib to be cleared from the system after the last dose.
It is an important consideration for managing toxicity (e.g., waiting for blood counts to recover after holding a dose) and for planning surgeries or other treatments.
Global Sourcing Tips of Niraparib API
For API importers and generic manufacturers, sourcing high-quality Niraparib API is paramount.
Verify Regulatory Status: Source from countries with stringent regulatory authorities. India and China are major hubs for API production. Ensure manufacturers are compliant with Good Manufacturing Practices (GMP) and have successfully passed FDA or EMA inspections.
Quality Over Price: While cost is a driver, never compromise on quality. Insist on a comprehensive Certificate of Analysis (CoA), Drug Master Files (DMF), and complete transparency on impurities and stability data.
Supply Chain Redundancy: The pandemic highlighted vulnerabilities in the supply chain. Diversify your supplier base to mitigate risk from regional disruptions. Consider having at least two qualified suppliers.
Intellectual Property (IP) Landscape: Be acutely aware of the patent status of Niraparib in your target markets. Sourcing an API for territories where the compound patent is still in force can lead to legal complications.
Reputable Suppliers: Partner with established and reputable manufacturers known for quality and reliability in oncology APIs.
Compounding Pharmacy Guidelines for Niraparib Formulations
While Niraparib is commercially available in capsule form, compounding pharmacies may be involved in specific scenarios:
Dose Alteration: Creating custom strengths (e.g., 50 mg capsules) for precise dose reduction in patients experiencing intolerable toxicity.
Alternative Formulations: For patients unable to swallow capsules, compounding into a liquid suspension might be necessary.
Critical Guidelines:
Stability: The commercial product is available in capsule form. Limited data exists on the stability of Niraparib in compounded forms. Conduct stability studies for any alternative formulation.
Bioavailability: Any change in formulation (e.g., crushing capsules to make a suspension) could affect bioavailability. It must be clearly communicated to the prescribing physician.
Contamination Control: As an antineoplastic agent, Niraparib must be handled in accordance with USP <800> guidelines to protect pharmacy personnel and prevent cross-contamination. It includes the use of a vertical laminar airflow containment primary engineering control (C-PEC) and appropriate personal protective equipment (PPE).
Patient Counseling: Compounded preparations must be accompanied by clear instructions on storage, handling, and administration to ensure safe use.
Niraparib Market Prospects
The future for Niraparib is exceptionally bright, driven by several factors:
Expanding Indications: Ongoing clinical trials are investigating the efficacy of niraparib in other solid tumors, including prostate cancer, breast cancer, and lung cancer. Success in these areas would dramatically expand the target market.
Combination Therapies: Research combining Niraparib with other agents, such as immunotherapies (e.g., Pembrolizumab) and targeted therapies, is a key growth area, potentially setting new standards of care.
Global Market Penetration: As more countries enhance their healthcare infrastructure and cancer care policies, access to high-cost targeted therapies is expected to increase, particularly in the Asia-Pacific and Latin America.
Biosimilars and Generics: The eventual expiry of core patents will open the floodgates for generic competition, making the drug more accessible and expanding the volume-based opportunity for API suppliers and generic manufacturers.
Table: Niraparib Market Drivers Analysis
| Market Driver | Impact Level | Explanation |
|---|---|---|
| Label Expansion | High | New cancer indications directly increase the eligible patient pool. |
| Combination Therapy Success | High | Creates new, larger treatment regimens that require niraparib. |
| Emerging Market Access | Medium-High | Rising incomes and better healthcare in APAC/LATAM drive demand. |
| Patent Expiration | Very High (for generics) | Dramatically lowers prices, increases volume, and allows generic entry. |
| Biomarker Testing Adoption | Medium | Widespread genetic testing identifies more eligible patients. |
Cost-Effective Bulk Purchasing Strategies for Niraparib API Importers
Forecast Accurately: Develop a robust demand forecasting model based on market analysis, patient numbers, and treatment duration to avoid overstocking or stockouts.
Long-Term Contracts: Negotiate volume-based pricing with key suppliers through long-term supply agreements to secure stable pricing and reduce costs. This locks in the price and ensures a stable supply.
Strategic Inventory: Maintain a buffer stock to protect against supply chain shocks, but avoid excessive inventory that ties up capital and risks expiry.
Monitor Patent Cliffs: The single most significant cost-reduction opportunity arises with patent expiration. Prepare generic product development and API sourcing strategies to coincide with patent expirations in key markets, enabling a first-to-market advantage.
Consider Pre-Formulated Options: Some suppliers offer “ready-to-press” granules or other semi-finished products, which can reduce manufacturing complexity and cost.
Conclusion
Niraparib stands as a testament to the power of precision medicine in oncology.
Its unique profile—characterized by once-daily dosing, efficacy across biomarker subgroups, and a manageable safety profile with individualized dosing—secures its essential position in the PARP inhibitor market.
For API importers, manufacturers, and compounding pharmacies, it represents a significant and growing opportunity.
Success in this space requires a deep understanding of its clinical use, a steadfast commitment to quality in sourcing and manufacturing, and a strategic eye on the evolving patent and regulatory landscape.
By providing a reliable, high-quality Niraparib formulation, industry players can make a meaningful contribution to patient care while establishing a strong position in a dynamic, valuable segment of the oncology market.
Disclaimer:
This content is for informational purposes only and is intended for business-to-business communication within the pharmaceutical industry. It is not intended as medical advice. The manufacture, import, and use of API must comply with all applicable laws and regulations in the relevant country or region.
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
